6-(1,3-dioxolan-2-yl)hexanoic acid | 436151-17-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-(1,3-dioxolan-2-yl)hexanoic acid
• CAS: 436151-17-6
• 化学式: C₉H₁₆O₄
• 分子量: 188.224
• InChiKey: ICJCKVXNUUGQFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(1,3-dioxolan-2-yl)hexanoic acid 、 苯胺 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以94%的产率得到6-(1,3-dioxolan-2-yl)-N-phenylhexanamide
  参考文献：
  名称：

  Synthesis and biological evaluation of aziridin-1-yl oxime-based vorinostat analogs as anticancer agents

  摘要：

  The suberoyl anilide hydroxamic acid (vorinostat) analogs with the aziridin-1-yl oxime moiety as a possible metal chelating functionality have been synthesized. Their biological activity and stability under physiological conditions have been evaluated. Although some of the synthesized compounds demonstrated high antiproliferative activity against human HT1080 fibrosarcoma (HT1080, IC50 0.3-7.7 mu M) comparable to vorinostat (HT1080, IC50 2.4 mu M), they showed only weak histone deacetylase inhibition activity in HeLa cell line extracts.

  DOI：

  10.1007/s10593-015-1752-z
• 作为产物：
  描述：

  7-羟基庚酸乙酯 在 对甲苯磺酸 、 pyridinium chlorochromate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 苯 为溶剂， 反应 3.0h， 生成 6-(1,3-dioxolan-2-yl)hexanoic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of aziridin-1-yl oxime-based vorinostat analogs as anticancer agents

  摘要：

  The suberoyl anilide hydroxamic acid (vorinostat) analogs with the aziridin-1-yl oxime moiety as a possible metal chelating functionality have been synthesized. Their biological activity and stability under physiological conditions have been evaluated. Although some of the synthesized compounds demonstrated high antiproliferative activity against human HT1080 fibrosarcoma (HT1080, IC50 0.3-7.7 mu M) comparable to vorinostat (HT1080, IC50 2.4 mu M), they showed only weak histone deacetylase inhibition activity in HeLa cell line extracts.

  DOI：

  10.1007/s10593-015-1752-z

文献信息

• Inhibitors of histone deacetylase
  申请人：——

  公开号：US20020177594A1

  公开（公告）日：2002-11-28

  Compounds having the formula 1 or therapeutically acceptable salts thereof, are histone deacetylase (HDAC) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

  具有以下化学式的化合物或其治疗上可接受的盐是组蛋白去乙酰化酶（HDAC）抑制剂。本文揭示了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• Nickel-Catalyzed Carboxylation of Organozinc Reagents with CO₂
  作者：Hidenori Ochiai、Minsul Jang、Koji Hirano、Hideki Yorimitsu、Koichiro Oshima

  DOI：10.1021/ol800764u

  日期：2008.7.3

  An efficient nickel catalyst system for the carboxylation of organozinc reagents with CO(2) under very mild conditions has been developed. The catalyst system complements the conventional methods and enables the direct synthesis of various saturated carboxylic acid derivatives from the corresponding alkylzinc reagents and CO(2).

  已经开发了一种在非常温和的条件下将有机锌试剂与CO（2）羧化的有效镍催化剂体系。该催化剂体系是对常规方法的补充，可以从相应的烷基锌试剂和CO（2）直接合成各种饱和羧酸衍生物。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：ABBOTT LAB

  公开号：WO2002046129A2

  公开（公告）日：2002-06-13

  Compounds having the formula or therapeutically acceptable salts thereof, are histone deacetylase (HDAC) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.
• Synthesis and biological evaluation of aziridin-1-yl oxime-based vorinostat analogs as anticancer agents
  作者：Anna Nikitjuka、Irina Shestakova、Nadezhda Romanchikova、Aigars Jirgensons

  DOI：10.1007/s10593-015-1752-z

  日期：2015.7

  The suberoyl anilide hydroxamic acid (vorinostat) analogs with the aziridin-1-yl oxime moiety as a possible metal chelating functionality have been synthesized. Their biological activity and stability under physiological conditions have been evaluated. Although some of the synthesized compounds demonstrated high antiproliferative activity against human HT1080 fibrosarcoma (HT1080, IC50 0.3-7.7 mu M) comparable to vorinostat (HT1080, IC50 2.4 mu M), they showed only weak histone deacetylase inhibition activity in HeLa cell line extracts.